乌司他丁联合替加环素对院内感染性重症肺炎患者的临床效果观察

CLINICAL EFFECT OF ULINASTATIN COMBINED WITH HEMATIGACYCLINE ON PATIENTS WITH NOSOCOMIAL SEVERE PNEUMONIA

目的 明确替加环素基础上加用乌司他丁对本院治疗期间发生感染性重症肺炎患者的治疗意义。方法 纳入2019年1月—2020年4月来该院接受治疗后发生重症肺炎的40例患者进行临床试验,按照抽签方式随机分组,使观察组和对照组均为20例。对照组于普通多见治疗的基础上静脉输入乌司他丁,观察组在此基础上联合注射替加环素。比较患者治疗有效率;对照二组TNF-α、IL-6、IL-8,SaO、PaO及PaO/FIO和不良反应发生率。结果 观察组联合用药后总有效率为90.00%高于对照组60.00%,差异显著(P<0.05)。比较两组二组不良反应总发生率,观察组更低,差异显著(P<0.05)。治疗后,观察组TNF-α,IL-6、IL-8水平显著低于对照组,SaO、PaO、PaO/FIO水平显著高于对照组(均P<0.05)。结论 对院内感染性重症肺炎患者在有效综合治疗基础上,采取乌司他丁联合血替加环素治疗的疗效明显,能有效提高治疗有效率,且具药物安全性较高,并降低患者体内炎症因子水平,提高其肺功能指标。

Objective To study the application value of ulinastatin combined with hemagglutinin in the treatment of severe hospital acquired pneumonia.Methods Forty patients with severe pneumonia after treatment in our hospital from January 2019 to April 2020 were included in the clinical trial.They were randomly divided into observation group and control group according to the way of drawing lots.The control group received intravenous infusion of ulinastatin on the basis of conventional basic treatment, and the observation group was injected with tigecycline on this basis.The clinical effective rate was compared;the levels of TNF-α,IL-6,IL-8,SaO,PaOand PaO/FiO,and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).Compared the total incidence of adverse reactions between the two groups, the observation group was lower, the difference was significant(P<0.05).After treatment, the levels of TNF-α,IL-6 and IL-8 in the observation group were significantly lower than those in the control group, and the levels of SaO,PaOand PaO/FiOin the observation group were significantly higher than those in the control group(all P<0.05).Conclusion Ulinastatin joint of blood for patients with nosocomial severe pneumonia can effectively improve the treatment efficacy, and lower the incidence of adverse reactions, with high safety, and can reduce the patient’s body inflammatory factor levels, as well as improve the lung function index.